Bioseeker, Feb 2011 Targets - A Growing Family
6.1 Challenges in Protein KinaseDrugDiscovery
6.1.1 Enabling Structure-Based Drug Design is the Key
6.1.2 Specific Kinase Inhibitors without Kinase Profiling?
6.2 Drugs
Jain PharmaBiotech, Feb 2012, Pages: 864
as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drugdiscovery as well
BioPharm Reports (VennBio Ltd.), Jan 2009, Pages: 235
includes proposed resistance mechanisms associated with CSCs, drugdiscoverystrategies for the targeting of these cells, the current CSC-targetingdrug development pipeline and the potential of these cells
Jain PharmaBiotech, Feb 2012, Pages: 345
of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS.
Various strategies that have been used for manipulating the blood-brain barrier
Jain PharmaBiotech, Feb 2012, Pages: 534
discovery
High through screening for AD drug candidates
Proteomics and drugdiscovery for AD
Small molecule compounds binding to neurotrophin receptor p75NTR
Targeting Vav in tyrosine kinase signaling
Decision Resources, Inc., Dec 2009, Pages: 38
of tyrosine kinase inhibitors? What potential new paradigm will emerge for drug regulatory agencies? What major strategy do companies employ when commercializing targeted cancer therapies?
- In the 12-month
Business Insights, Jan 2008, Pages: 253
the forecast period.
- Bioinformatics-enabled protein biomarker discovery will enable the development of safer and more effective drugs, targeted therapies and molecular diagnostics.
- Systems biology modelling
Bioseeker, Dec 2006, Pages: 550
assessment of the targeted oncology market place; Including more than 340 drugs and pharmaceutical companies
- Thorough review of six major targetingstrategies in oncology: Apoptosis agents, Protein kinase
Jain PharmaBiotech, Feb 2012, Pages: 532
of chronic pain
Role of glia in neuropathic pain
Molecular and neurobiological techniques
Improved understanding of cancer pain
Advances in drugdiscovery and development for pain
Novel targets for drug
Business Insights, Nov 2009, Pages: 165
Introduction
Application in R&D & technological advances
Exploring new therapeutic targets
Epigenetic market, leading companies & pharmaceutical strategies
The future of epigenetics
Chapter 1 Introduction
Datamonitor, April 2010, Pages: 243
with greater efficacy
Small molecules
Small molecules targeting tyrosine kinases have been a significant development in oncology drugdiscovery
Classification of pipeline products
Angiogenesis inhibitor
Global Industry Analysts, Inc., Oct 2011, Pages: 897
of Molecular Targeted Therapies under Pipeline by
Drug Class as of 2010 (includes corresponding Graph/Chart) 31
Types of Targeted Therapy 31
Tyrosine Kinase Inhibitors 31
List of Approved Tyrosine Kinase
Global Industry Analysts, Inc., Feb 2011, Pages: 682
By Type 11
Small Molecule Tyrosine Kinase Inhibitors 12
Inhibitors of mTOR 13
Other Anti-Angiogenic Agents 13
Leading Drugs in the Market 14
Avastin Leads the Fray 14
Table 2: Select Leading Drugs
Global Industry Analysts, Inc., Sep 2010, Pages: 694
8
Transformation of DrugDiscovery through Proteomics and Genomics 9
Proteomics: A Critical DrugDiscovery Tool 9
Global Proteomics Sample
Global Industry Analysts, Inc., Aug 2011, Pages: 1305
, transcriptomic, peptidomic, glycoproteomic, proteomic and pharmacogenomic technology platforms that target biomarker qualification, discovery, and development. The advancements in this segment is likely
Global Industry Analysts, Inc., April 2009, Pages: 739
Appear Over the Horizon II-4
New Generation Prostate Cancer Drugs and Their Area of Use II-4
Small Cap Companies: A Target of Private Capital Financing
Life Science Intelligence, Inc., Dec 2011, Pages: 605
Epidermal System) - a novel transdermal delivery device for high molecular weight drugs, that can be used by medical personnel or the patient
- Ozone injection system for multiple spinal applications
Informa Healthcare, Jan 2006, Pages: 170
, Middlesex, UK), a dual tyrosine kinase inhibitor that targets EGFR and HER2. This capacity considerably expands the therapeutic potential of this drug with potential for overcoming drug resistance that may
Lead Discovery, Nov 2002
and chief analyst at LeadDiscovery and coordinates the identification of candidate drugdiscovery projects with industrial potential. Glycogen synthase kinase 3 inhibitors: Proof of concept and therapeutic
